Market News & Trends
Aptar Pharma Launches New Portable & Ready-to-Use Upper Respiratory Drug Delivery Solution
Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care.
Ajinomoto Althea & OmniChem Combine to Form Ajinomoto Bio-Pharma Services
Ajinomoto Althea and OmniChem, global leaders in large and small molecule contract manufacturing services, recently announced they are integrating their businesses and operations as a…
Cerecor to Acquire Ichorion Therapeutics; Transaction Worth $26.6 Million
Cerecor Inc. recently announced it has agreed to acquire Ichorion Therapeutics, Inc. Ichorion is a privately-held biopharmaceutical company focused on developing treatments and increasing awareness…
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials
Ovid Therapeutics Inc. recently announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports…
VisionGate Presents Breakthrough Research on Cell-CT Platform
VisionGate recently presented two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC)…
Cobra Biologics, GE Healthcare & Centre for Process Innovation Collaborate to Advance Gene Therapy
Cobra Biologics recently announced a collaboration with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences. The three-way…
Immutep Enters Into Clinical Trial Collaboration & Supply Agreement With Merck & Pfizer
Immutep Limited recently announced it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate…
Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
Brammer Bio Announces Progress on $200-Million Program to Advance Gene Therapies
Brammer Bio recently announced that a 3-year, $200-million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies
GB Sciences, Inc. and Catalent Pharma Solutions recently announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (APIs) for its Parkinson’s disease therapies.
Inovio Develops Novel H3N2 Influenza DNA Vaccine; Generates Cross-Reactive Responses & Provides Complete Protection Against Lethal Preclinical Challenges
Inovio Pharmaceuticals, Inc. recently announced its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains…
ProMach Acquires FLtecnics, Leading Manufacturer of Horizontal-Form-Fill Seal Pouch Packaging Solutions
ProMach continues to expand its global footprint and flexible packaging product line with the acquisition of FLtècnics of Girona, Spain. ProMach's relationship with the European…
ContraVir Pharmaceuticals Announces Completion of Phase 1 With CRV431
ContraVir Pharmaceuticals, Inc. recently announced that the primary endpoints of safety and tolerability were met in a single ascending dose (SAD) study of CRV431 conducted…
Neurimmune Achieves Milestone in Collaboration With Ono Pharmaceutical
Neurimmune recently announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered…
Lonza Launches Early-Intermediates Supply Initiative for Small-Molecule APIs
Lonza Pharma & Biotech recently announced the launch of its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp (CH)…
Beta Bionics Secures $50-Million Financing for Bionic Pancreas
Beta Bionics, Inc. recently announced it has so far raised $50 million of a Series B equity financing. The round was led by Eventide Asset Management,…
Thermo Fisher Scientific to Launch Global Customer Solution Centers
Thermo Fisher Scientific Inc. recently announced its intent to open multiple Global Customer Solution Centers. The new Global Customer Solution Centers will focus on meeting and exceeding the demands of scientists in food, beverage, pharmaceutical and biotech laboratories by developing critical workflows and integrated solutions that help advance chromatography and mass spectrometry worldwide.
Molecular Templates Announces Agreement With Takeda for Joint Development of Protein-Based Oncology Therapy
Molecular Templates, Inc. recently announced an agreement with Takeda Pharmaceutical Company Limited for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.
Evonik Completes Multi-Million Dollar Expansion of its CMO Capabilities for API & Advanced Intermediates
Evonik, a global CMO leader for API and advanced intermediates, recently announced the completion of a 36-million euro expansion of its contract manufacturing capabilities in the US and Europe.
PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging
PCI Pharma Services recently announced the acquisition of San Diego-based Sherpa Clinical Packaging, which expands PCI’s US operations to the West Coast. The acquisition of…
